Role of Percutaneous Coronary Intervention (PCI) in Treating Coronary Artery Disease

Indications for PCI

The American College of Cardiology recommends PCI as a valuable initial mode of revascularization in patients with stable coronary artery disease (CAD) who have objective evidence of large ischemia in the presence of almost any lesion subset, except chronic total occlusions that cannot be crossed 2
The American College of Cardiology suggests PCI is beneficial for symptom improvement in patients with one or more significant (>70% diameter) coronary artery stenoses amenable to revascularization and unacceptable angina despite guideline-directed medical therapy 1
The American College of Cardiology recommends PCI for symptom relief in patients with significant stenoses and unacceptable angina when medical therapy cannot be implemented due to contraindications, adverse effects, or patient preferences 1

In patients with non-ST-elevation acute coronary syndromes (NSTE-ACS), the European Society of Cardiology recommends early angiography (≤48 hours) and, when needed, PCI shows clear benefit only in high-risk groups 2, 3
For ST-elevation myocardial infarction (STEMI), the European Society of Cardiology recommends primary PCI as the treatment of choice in patients presenting to hospitals with PCI facilities and experienced teams 2, 4
The European Society of Cardiology suggests primary PCI is superior to thrombolysis for STEMI treatment, with better outcomes including lower rates of death, non-fatal reinfarction, stroke, and recurrent ischemia 4, 5

The American College of Cardiology recommends CABG over PCI to improve survival in patients with complex 3-vessel CAD (e.g., SYNTAX score >22) with or without involvement of the proximal LAD artery 1
The American College of Cardiology suggests CABG is generally preferred over PCI for patients with multivessel CAD and diabetes mellitus, particularly if a left internal mammary artery graft can be anastomosed to the LAD artery 1, 6
The American College of Cardiology recommends against PCI in patients with significant left main coronary artery disease who are candidates for CABG 6

The COURAGE trial showed patients randomized to PCI had small but significant benefits in terms of less angina frequency, better physical functional status, and better quality of life over 6-24 months after randomization, though health status outcomes were equivalent at 36 months 9

The relationship between ACC/AHA guideline-recommended indications for PCI and outcomes has been demonstrated, with clinical success declining across indication classes (Class I: 92.8%, Class IIa: 91.7%, Class IIb: 89%, and Class III: 85.5%) 10

The European Society of Cardiology recommends routine coronary angiography within 24 hours and PCI, if applicable, after successful thrombolysis, even in asymptomatic patients without demonstrable ischemia to improve outcomes 2

The American College of Cardiology recommends against PCI if the patient is not likely to tolerate and comply with dual antiplatelet therapy for the appropriate duration based on the type of stent implanted 1
The European Society of Cardiology suggests a higher level of experience and patient volume is required for primary PCI than for PCI in patients with stable CAD 4
The European Society of Cardiology recommends primary PCI should be directed only at the infarct-related coronary artery (culprit vessel), with decisions about PCI of non-culprit lesions guided by objective evidence of residual ischemia at later follow-up 4

The American College of Cardiology recommends against PCI in patients who do not meet anatomic (>50% left main or >70% non-left main stenosis) or physiological criteria for revascularization 1
The American College of Cardiology suggests the usefulness of PCI to improve survival is uncertain in patients with 2- or 3-vessel CAD (with or without involvement of the proximal LAD artery) or 1-vessel proximal LAD disease 1